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ABSTRACT
Most E2F-binding sites repress transcription through
the recruitment of Retinoblastoma (RB) family mem-
bers until the end of the G1 cell-cycle phase. Al-
though the MYB promoter contains an E2F-binding
site, its transcription is activated shortly after the exit
from quiescence, before RB family members inacti-
vation, by unknown mechanisms. We had previously
uncovered a nuclear factor distinct from E2F, Myb-
sp, whose DNA-binding site overlapped the E2F el-
ement and had hypothesized that this factor might
overcome the transcriptional repression of MYB by
E2F-RB family members. We have purified Myb-sp
and discovered that Myc-associated zinc finger pro-
teins (MAZ) are major components. We show that
various MAZ isoforms are present in Myb-sp and ac-
tivate transcription via the MYB-E2F element. More-
over, while forced RB or p130 expression repressed
the activity of a luciferase reporter driven by the MYB-
E2F element, co-expression of MAZ proteins not only
reverted repression, but also activated transcription.
Finally, we show that MAZ binds the MYB promoter in
vivo, that its binding site is critical for MYB transac-
tivation, and that MAZ knockdown inhibits MYB ex-
pression during the exit from quiescence. Together,
these data indicate that MAZ is essential to bypass
MYB promoter repression by RB family members and
to induce MYB expression.
INTRODUCTION
The proto-oncogene MYB was initially identified as a fre-
quent integration site for avian and murine retroviruses,
leading to a range of leukemias (1). In addition, MYB
overexpression was found in several other cancer types, in-
cluding neuroblastoma, melanoma, glioblastoma and neo-
plasias from colon, pancreas and breast (2,3). MYB encodes
a sequence-specific DNA-binding transcriptional regulator
that is highly expressed in embryonic nervous system, liver,
kidney and colon mucosa. In the adult, its expression lev-
els are high in epithelial progenitor cells in colon crypts;
hematopoietic progenitors; activated mature T and B lym-
phocytes; and ependymal cells, progenitor cells and some
neuroblasts located at neurogenic regions in the subventric-
ular zone of adult brain (2,3). MYB, also known as proto-
oncogene C-MYB, plays a central role in the regulation of
hematopoietic cell development, and the control of its ex-
pression is critically important in cell proliferation and dif-
ferentiation of both normal and tumor cells. Indeed, MYB
anti-sense oligonucleotides inhibit cell proliferation and its
forced expression blocks cell differentiation (3,4). In addi-
tion, the analysis of Myb-targeted mice demonstrated a crit-
ical role for Myb in fetal hematopoiesis and colon develop-
ment (1,3).
In normal cells, MYB expression is tightly regulated at
transcriptional and post-transcriptional levels. However, in
spite of its critical relevance, the regulation of MYB ex-
pression is not well understood. MYB is not expressed in
quiescent cells, but its transcription is promoted shortly af-
ter the stimulation of cell proliferation. Its promoter lacks
canonical TATAA and CAAT boxes, but harbors several
GC boxes and binding sites for various transcriptional reg-
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ulators. In particular, the human and mouse promoters con-
tain a binding site for members of the E2F family of tran-
scriptional regulators (5,6). This family plays a central role
in cell cycle regulation by restricting genes expression to the
precise time of the cell cycle in which their products are re-
quired (7). Most E2F factors are composed of two subunits,
termed E2F and declustering potential (DP), which form
heterodimeric complexes. Eight E2F genes (E2F1-E2F8)
and two DP genes (DP1 and DP2) are expressed in mam-
mals. The Retinoblastoma tumor suppressor protein (RB)
and its family members p107 and p130 bind to E2F factors
and block their transactivation capacity. The recruitment of
RB family members to gene promoters exerts a dominant
negative effect on their transcription due to the association
of RB and its family members with chromatin remodelers
(8,9). The RB family member p130 is particularly essential,
as a component of the dimerization partner, RB-like, E2F
and multi-vulval class B (DREAM) complex, for repression
of E2F-regulated genes in quiescent cells (9,10). RB fam-
ily members are inactivated by phosphorylation mediated
by cyclin-dependent kinases (CDKs) at the G1-S boundary
and thus release E2F repressors from promoters and en-
able transcriptional activation (7). As a consequence, most
genes that contain E2F elements are not transcriptionally
activated before the G1-S transition. MYB, however, is an
exception to this rule; although MYB contains an E2F el-
ement and can be induced by forced E2F1 expression (6),
its induction occurs early after the exit from quiescence
(11,12), before RB family inactivation and remains consti-
tutive in subsequent cell cycles (12). These results indicated
that MYB is able to escape from the dominant transcrip-
tional repression of E2F–RB family complexes during spe-
cific times of G1.
We hypothesized that the interaction of proteins distinct
from E2F with the MYB-E2F site might account for the
early activation of its promoter. We had previously discov-
ered a nuclear factor, referred to as Myb-sp, that contained
no E2F/DP or RB family members and specifically inter-
acted with the MYB-E2F site, but not with the E2F ele-
ment from other promoters (5). However, the identity of
this factor remained elusive. Here we have identified Myc-
associated zinc finger proteins (MAZ) as major components
of Myb-sp and demonstrated their capacity to overcome
transcriptional repression by RB family members through
the MYB-E2F element. We also show that MAZ proteins
are essential mediators of MYB induction during the exit
from quiescence.
MATERIALS AND METHODS
Cell culture and preparation of nuclear extracts and in vitro-
translated proteins
DG-75 and Jurkat cells were grown in RPMI 1640 medium,
whereas Saos-2 and human embryonic kidney 293T (HEK-
293T) cells were grown in Dulbecco’s modified Eagle’s
medium. Both media were supplemented with 10% fe-
tal bovine serum (FBS), penicillin, streptomycin and L-
glutamine. All cells were maintained at 37◦C in a humidi-
fied 5% CO2-containing atmosphere. Buffy coats of healthy
individuals were obtained from the Madrid Blood Donor
Centre (Madrid, Spain). Human peripheral blood lympho-
cytes (PBLs) were isolated from buffy coats as described
previously (13) and then stimulated with 5 g/ml leuco-
agglutinin (L4144; Sigma-Aldrich, Madrid, Spain) and cul-
tured in RPMI 1640 medium supplemented with 10% FBS,
penicillin, streptomycin, L-glutamine and 50 U/ml of hu-
man recombinant interleukin 2 (IL2) (14). Cell cycle syn-
chronization of lymphocytes was done as described (15).
Briefly, after 12 days, blast cells were turned quiescent by
transferring them to medium without IL2 and 2 days later
cells were induced to exit quiescence by stimulation with 5
g/ml leucoagglutinin plus 50 U/ml of IL2. Institutional
Review Board approval was obtained for these studies and
all participants provided written informed consent. Nu-
clear extracts were prepared as previously reported (16).
pcDNA3-HA-MAZ-1 or -MAZ-2s were in vitro transcribed
and translated by using TnT® coupled reticulocyte lysate
systems (L-4610; Promega, Madison, WI, USA) following
manufacturer recommendations.
Antibodies and immunoblotting
The anti-MAZ MAZ-N12, MAZ-C13, MAZ-C2 and
MAZ-123 polyclonal rabbit sera were raised against KLH-
conjugated peptides derived from the amino- or carboxy-
terminal regions of Human MAZ proteins. Antibodies
against HA (MMS-101P), SMAD2/3 (sc-6032x) and Tubu-
lin (T9026) were purchased from Covance (Covance), Santa
Cruz (Santa Cruz, CA, USA) and Sigma-Aldrich, respec-
tively. The anti-DP1 polyclonal rabbit antibody was de-
scribed previously (5). For immunoblotting, we used an-
tibodies to MAZ, MAZ phospho-S460 (sc-16318, Santa
Cruz), E2F1 (sc-193x, Santa Cruz), pRB (554136, BD
Biosciences Pharmingen), p130 (sc-374521, Santa Cruz),
p130 phospho-S672 (ab76255, Abcam), Tubulin (T9026,
Sigma-Aldrich) and a combination of RB phospho-
S780, phospho-S795 and phospho-S807/811 (8180, 9301
and 8516 from Cell Signaling), followed by peroxidase-
conjugated anti-rabbit (A1949) or anti-mouse (A2304)
antibodies (Sigma-Aldrich). Chemiluminescent detection
reagent (Perkin-Elmer, Waltham, MA, USA) was used and
the membrane exposed to X-Ray Medical film.
Electrophoretic mobility shift analysis
Gel shifts were performed with labeled double-stranded
oligonucleotides (Sigma–Aldrich) encompassing the E2F
elements from the MYB, DHFR and CDC2 promoters. The
sequences of these oligonucleotides (5′ to 3′) were: MYB
(CTAGACAGATTTGGCGGGAGG GGGG and GATC
CCCCCCTCCCGCCAATCTGT); DHFR (CTAGAGCA
ATTTCGCGCCA AACTTG and GATCCAAGTTTG
GCGCGAAATTCGT); and CDC2 (CTAGATTTCTTT
CG CGCTCTAGCCG and GATCCGGCTAGAGCGC
GAAAGAAAT). The top-strand oligonucleotide sequence
(5′ to 3′) of the MYB-E2F mutants was: MYB-Sp (CT
AGAC AGATTTATAGGGAGGGGGG), MYB-E2F (CT
AGACAGATTTGGCGGGAGATGGG) and MYB-Null
(CTAGACAGATTTATAGGGAGATGGG). Binding re-
actions were performed in buffer D (BFD) (20 mM HEPES
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aminetetraacetic acid, 0.5 mM dithiothreitol (DTT)) sup-
plemented with sheared salmon sperm DNA and purified
bovine serum albumin (BSA), as described previously (13).
Unlabeled oligonucleotide competitors (100 ng) and anti-
bodies (1 g of purified antibodies or 1 l of crude poly-
clonal antibodies) were also added to the initial mix prior
to the pre-incubation step. Following pre-incubation, the
labeled oligonucleotides were added (1 ng) and the mix-
tures were incubated for another 20 min at room temper-
ature. Samples were then loaded directly onto a running
non-denaturing 4% acrylamide-0.1% bisacrylamide gel at
4◦C. Retarded complexes were visualized by autoradiogra-
phy (1–16 h at room temperature).
UV cross-linking experiments
Ultraviolet (UV) cross-linking of DNA/protein complexes
was carried out essentially as described (13). Bromod-
eoxyuridine (BrdU)-substituted 32P-labeled probes were
prepared by annealing the oligonucleotide primer UV-
common (5′-GATCCACTGAGCCT-3′) with the E2F-c-
myb-UV oligonucleotide (CTAGACAGATTTGGC GG
GAGGGGGAGGCTCAGTG-3′). Labeling (200 ng) was
achieved by a Klenow fill-in reaction performed for 1–2 h
at 4◦C with [-32P]dGTP and [-32P]dCTP and unlabeled
dATP and bromo-dUTP (Sigma-Aldrich) in the labeling re-
action. Unincorporated nucleotides were removed by chro-
matography over Sephadex G25. Electrophoretic mobility
shift analyses (EMSAs) were performed with the BrdU-
substituted probes as described above except that the bind-
ing reaction was scaled-up 2-fold. Immediately after elec-
trophoresis, the wet gel was covered with plastic wrap and
exposed to UV light (500 mJ) with a Stratalinker 1800 (Agi-
lent Technologies, Santa Clara, CA, USA). The positions of
various complexes were determined by 1–2 h autoradiogra-
phy at 4◦C. Gel slices containing various complexes were ex-
cised and soaked in 50–100 l of 2× sodium dodecyl sulfate
(SDS) sample buffer at 65◦C for 30 min. The samples were
boiled for 5 min and electrophoresed through an SDS-8%
polyacrylamide gel along with pre-stained molecular weight
markers (BioRad Laboratories, Hercules, CA, USA).
Purification and identification of Myb-sp






subjected to 5′-phosphorylation and concatemerized with
DNA ligase. The concatemerized DNA (100 g) was
coupled to 1 ml of cyanogen bromide-activated-Sepharose
4B (17–0430-01, Amersham) and loaded onto columns that
were then equilibrated in BFD80 (as BFD except that KCl
was used at 80 mM). Nuclear extracts from 109 DG-75 cells
were pre-cleared by partial protein precipitation with 25%
acetone (2 h at 4◦C). Acetone was evaporated during 1 h at
4◦C in a vacuum chamber and samples were centrifuged 15
min at 17 000 × g at 4◦C. Supernatant was dialyzed against
BFD80 and then loaded onto a column prepared with
Myb-Null-ac-coupled resin. The flow-through was loaded
in a column prepared with Myb-Sp-ac-coupled resin and
both columns were washed with three volumes of BFD80
supplemented with 1% NP40, two volumes of BFD80,
three volumes of BFD150 (as BFD except that KCl was
used at 150 mM) and two volumes of BFD80. Bound
proteins were eluted with 300 ng/l of double-strand
Myb-Sp-ac oligonucleotides in BFD. All buffers contained
1 mM PMSF, 1 mM Na3VO4 and 1 mM NaF added
immediately before use. Eluted proteins were precipitated
with 10% tri-chloro-acetic acid and fractionated through
10% sodium dodecyl sulphate-polyacrylamide gel elec-
trophoresis (SDS-PAGE). A silver-stained band at 30 kDa
in the Myb-Sp column was excised from the gel, subjected
to tryptic digestion and analyzed by mass spectrometry
at the proteomics facility of The Spanish National Center
for Biotechnology (CNB-CSIC; Madrid, Spain). Bands
of interest were trypsin-digested by automated in-gel
digestion in a Proteineer DP (Bruker Daltonics). Tryptic
peptides were extracted and analyzed by LC-MS/MS using
a nano-HPLC system (Eksigent Technologies nanoLC
Ultra 1D plus, AB SCIEX) coupled online to a TripleTOF
5600 mass spectrometer (AB SCIEX) with a nano-spray
ionization source. The analytical and trap columns were
a nano-Acquity UPLC column (1.7 m, BEH 130 C18;
Waters) and a nanoViper column Acclaim PepMap C18,
5 m (Thermo Fisher Scientific), respectively. The loading
pump delivered 0.1% formic acid in water at 2 l/min;
the nanopump provided a flow rate of 250 nl/min and
was operated in gradient elution conditions with 0.1%
formic acid in water as mobile phase A, and 0.1% formic
acid in acetonitrile (ACN) as mobile phase B. Gradient
elution was performed as follows: 98% A:2% B for 1 min,
a linear increase to 30% B in 110 min and to 40% B in
10 min, then to 90% B in 5 min; isocratic conditions of
90% B for 5 min and return to initial conditions in 2 min.
One-third of the sample was processed by nanoLC-MS
in a 5-l injection volume. Settings for TripleTOF were:
ionspray voltage floating (ISVF) = 2800 V, curtain gas
(CUR) = 20, interface heater temperature (IHT) = 150,
ion source gas 1 (GS1) = 30, DP = 85 V. Data were
acquired in an information-dependent acquisition (IDA)
mode with Analyst TF 1.7 software (AB SCIEX). For IDA
parameters, a MS survey scan (250 ms) in the mass range
of 350–1250 m/z was followed by 25 MS/MS scans (100
ms) in the mass range of 100–1500 m/z. Switching criteria
set to ions greater than m/z = 350 and smaller than m/z
= 1250, with a charge state of 2–5, threshold >90 counts
(cps) and dynamic exclusion of 20 s. Collision energy (CE)
was set as rolling CE using a parameter script.
MS and MS/MS data were processed using Analyst TF
1.7 Software. Raw data were translated to mascot general
file (mgf) format using the PeakView program v.1.2 and
a Uniprot database (26 March 2014) with human taxon-
omy restriction (NEWT 9606), containing 39 785 protein-
coding genes and their reverse entries in an in-house Mas-
cot Server v.2.5.1 (Matrix Science). Search parameters were
as follows: fixed modification of carbamidomethyl cysteine;
variable modifications oxidation of methionines and acety-
lation of the peptide N-termini; peptide mass tolerance
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of two trypsin digestion missed-cleavages. Typical MS and
MS/MS spectra accuracy was ±10 ppm. Criteria to ac-
cept individual spectra were based on Mascot ion score
threshold (0.05) as the standard ion score threshold, and
the identification certainty was established using false dis-
covery rate criteria (FDR ≤ 1%) for peptide and protein
matches using the Scaffold bioinformatic tool v.4.2.1 (Pro-
teome Software). This cutoff value for protein identifica-
tion corresponded to a Mascot score of protein identifica-
tion of 25. A. The mass spectrometry proteomics data have
been deposited to the ProteomeXchange Consortium via
the PRIDE (17) partner repository with the dataset iden-
tifier PXD006857 and 10.6019/PXD006857.
Construction of vectors
Full-length MAZ-1, MAZ-2 and MAZ-2s coding se-
quences were obtained by polymerase chain reaction
(PCR) amplification from cDNA obtained from DG-75
cells and cloned immediately downstream from the HA-tag
into pcDNA3 (ThermoFischer Scientific, Waltham, MA







GGGGGG. MAZ-1, MAZ-2 and MAZ-2s cDNAs were
generated employing, respectively, MAZ-1/2Forward and
MAZ-1Reverse, MAZ-1/2Forward and MAZ-2Reverse
and MAZ-2sForward plus MAZ-2Reverse.
pBG-LUC was described previously (18) and was
generated by cloning the ß-globin TATA box im-
mediately upstream from the luciferase gene in the
pGL2-basic plasmid. To generate the wild-type (WT)
version of 2xE2F/MAZ-Luc and its mutant deriva-














cleotides were ligated to pBG-LUC, immediately upstream
from the ß-globin TATA box.
To generate MYBpr-Luc and its mutant derivatives,
PCR products encompassing the MYB promoter (−687 to
+5 relative to the transcription start site) were obtained
from myb(WT)-Luc, myb(E2F)-Luc, myb(myb-sp)-Luc
and myb(null)-Luc (5) and cloned into pGL2-Basic. PCR
primer sequences were as follows (5′-3′): GACTTCGGAT
CCGGGAGGGAGTGAA AGCTC and GAAGTCGG
ATCCTTAAAGTGTAAACTCTGTAAACAG. To gener-
ate MYBpr(+205)-Luc and its mutant derivatives, the
MYB 5′UTR was obtained from B1-CAT (19) and cloned
directly downstream from the WT or mutant versions of the
MYB promoter into MYBpr-Luc.
Knockdown plasmids were generated by cloning MAZ-
specific shRNAs (shMAZ-A and shMAZ-B) or a control
shRNA into the lentiviral plasmid, pLVTHM (a gift
from D. Trono’s lab). The shRNA sequences used (5′-3′)













CCTTGATATTAATTTTTTAT and CGATAA AAAA
TTAATATCAAGGGACACAATCAGTATTACTCT
AGATGTAATACTGCTTGTGTCCCTTGATATTAAA.
All plasmids were sequence verified.
Chromatin immunoprecipitation (ChIP)
Chromatin immunoprecipitation (ChIP) was done as de-
scribed (16) with modifications to enable lymphocytes chro-
matin fragmentation. Briefly, cells were treated with 1%
formaldehyde for 10 min at RT and subsequently with
1.25 M glycine for 5 min. Nuclei were frozen at −80◦C
before treating them with 0.15 u micrococcal nuclease
(8805, Thermo Scientific) for 5 min at 37◦C. Reaction was
stopped with 1% SDS plus 5 mM Ethylene glycol-bis(2-
aminoethylether)-N,N,N′,N′-tetraacetic acid (EGTA). Di-
gested chromatin was sonicated (8 pulses of 30 s) in a
sonicator bath and cell debris was eliminated by centrifu-
gation (15 min, 17 000 × g, 4◦C). The average DNA
length achieved was 200–600 bp. Fragmented chromatin
was pre-cleared with protein A-Sepharose beads (prein-
cubated with sonicated salmon sperm DNA, BSA and
normal rabbit serum) and immunoprecipitated with Rab-
bit anti-mouse IgG (M7023, Sigma), anti-MAZ M-123
or anti-RNA Polymerase II (MMS-126R; Covance). Im-
munoprecipitated complexes were collected with Protein
A-Sepharose beads pre-incubated with sonicated salmon
sperm DNA and BSA. The beads were washed and eluted,
and DNA was extracted from the eluates according to the
ChIP Assay Kit protocol (Upstate). One-third of the final
volume was analyzed by Syber-Green real time PCR using
the following oligonucleotides:
DNA was analyzed by Sybr Green real-time PCR using
specific primers that amplified the MYB promoter, the
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CAAGGCCGT), Bmp7-R (CGGAGGAT CCCTCCTTC-
CCAGTAACC).
Transfections and reporter gene assays
Saos-2 and HEK-293T cells were transfected by employing
the calcium phosphate method (20). Transfections of Saos-2
cells included 10 g of appropriate firefly luciferase reporter
plasmid plus 0.1 g of pRL-Null (Promega, Madison, WI,
USA) and 20 g of carrier plasmid (Bluescript; Stratagene,
Agilent Technologies, Santa Clara, CA, USA). Where in-
dicated, pRc-CMV-E2F1 plus pRc-CMV-DP1, pcDNA3-
HA-RB, pcDNA3-HA-p130 and/or increasing amounts of
pcDNA3-HA-MAZ1, -MAZ2 or -MAZ-2s were also used.
In control transfections, mock pcDNA3 or pRc-CMV was
used. PBLs were harvested and resuspended at a density of
1 × 108 cells/ml in RPMI 1640 and, then, electroporated
as described previously (21). Transfected PBLs were split in
two 35-mm-diameter dishes, incubated in RPMI with 10%
FCS at 37◦C and activated or not with 5 g/ml leucoagglu-
tinin (Sigma–Aldrich) plus 50 U/ml IL-2 for 24 h. PBLs
transfection included 40 g MYBpr(+205)-Luc reporter
vectors and 5 g pRL-SV40 (Promega Biotech, Madrid,
Spain). Firefly and Renilla luciferase activities were assayed
using Dual Luciferase Reporter Assay System (Promega).
Firefly luciferase activity was normalized with that of Re-
nilla luciferase.
Lentiviral production and infection
Lentivirus expressing green fluorescent protein (GFP) and
MAZ-specific shRNAs or scrambled shRNA sequences
were obtained, as previously described (22), by transient
calcium-phosphate transfection of HEK-293T cells, using
pLVTHM, psPAX2 and pMD2G-VSVG plasmids provided
by D. Trono (Ecole Polytechnique Federale de Lausanne,
Lausanne, Swisse). The supernatant containing the lentivi-
ral particles was collected 48 h after removal of the calcium
phosphate precipitate, filtered through a 45-M polyvinyli-
dene difluoride (PVDF) membrane (Steriflip; Millipore),
concentrated by ultracentrifugation (88 000 × g, 2 h at 4◦C)
and stored at −80◦C. Functional viruses were titrated by in-
fecting Jurkat cells with limiting virus dilutions and quan-
tification of GFP positive cells by flow cytometry after 24
h. Similar infection efficiencies with the different constructs
were found across experiments. IL2-dependent, proliferat-
ing lymphocytes (107 cells) were infected 10 days after leuco-
agglutinin stimulation by adding lentivirus particles (MOI
= 50) and incubating for 48 h. At this time, blast cells were
≥98% positive for CD3 expression (a marker of T lympho-
cytes) as determined by flow cytometry analysis. Cells were
subsequently washed with RPMI 1640 medium and trans-
ferred to culture medium without IL2. Two days later, cells
were stimulated again with 5 g/ml leucoagglutinin plus 50
U/ml of IL2 or left untreated. Infection efficiency (GFP ex-
pression) was monitored by flow cytometry.
Quantitative PCR analysis
Total RNA was extracted from 5 × 106 lymphocytes us-
ing RNeasy (74104; Qiagen, Venlo, Netherlands). The
genomic facility at Instituto de Investigaciones Biomed-
icas synthesized complementary DNA using M-MLV
retro transcriptase (ThermoFischer Scientific) and an-
alyzed gene expression by real-time quantitative (RT-
qPCR) as described (23) using TaqMan Gene Expres-
sion Assays (ThermoFischer Scientific) specific for hu-
man MAZ (Hs00911157 g1), MYB (Hs00193527 m1),
CYCNG2 (Hs00171119 m1), E2F1 (Hs00153451 m1) and
GUSB (Hs99999908 m1). GUSB was chosen as a control
gene on the basis of its homogeneous expression in stimu-
lated and untreated lymphocytes. Each gene expression ex-
periment was performed at least three times and calcula-
tions were made from measurements of three replicates of
each sample.
Immunofluorescence
Primary lymphocytes cultured on poly-Lys-coated cover-
slips were fixed with 4% paraformaldehyde (PFA), per-
meabilized with 0.1% Triton X-100 in phosphate-buffered
saline (PBS) for 5 min and then incubated in 4% BSA
in PBS for 30 min. Coverslips were then incubated for 1
h at room temperature with anti-CD45 D3/9 (a gener-
ous gift of Dr F. Sanchez-Madrid) and anti-phospho-MAZ
(S460) in blocking solution followed by the corresponding
secondary antibody. The nuclei were stained with DAPI
and coverslips were mounted with Prolong medium (Ther-
moFisher Scientific, Waltham, MA, USA). Confocal mi-
croscopy images were acquired using plan-apochromatic
objectives in an inverted Zeiss LSM 710 laser-scanning mi-
croscope (Zeiss, Germany). Sequential scanning mode was
used to avoid crosstalk between channels. All images shown
correspond to single sections. Pictures were processed with
Zen 2009 (Carl Zeiss MicroImaging) and Adobe Photoshop
CS (Adobe Systems Inc.) software.
Statistical analysis
Experiments were performed at least three times. Graphpad
Prism software 6.01 was used for the analysis. Differences
were analyzed by one-way or two-way analysis of variance
(ANOVA) with Bonferroni post-tests, as appropriate. Dif-
ferences were considered significant at P < 0.05.
RESULTS
Myb-sp contains a 30 kDa DNA-binding protein
EMSA of nuclear extracts from the B-cell line DG-75
and the E2F element in the MYB promoter (MYB-E2F)
showed, as previously described with other cells (5), four
major protein complexes (I–IV) that are common to other
E2F probes (Figure 1A). In addition, the MYB-E2F site
formed an additional complex (complex V) that was not
observed with any of the other E2F elements (Figure 1A).
While complexes I to IV contained E2F/DP heterodimers
associated to p107 (complex I), RB (complex II) or to no
RB family member (complexes III and IV), complex V con-
tained no DP/E2F factors (5). Given the specificity of com-
plex V, its constituent nuclear factor was named Myb-sp (5).
Since Myb-sp did not contain any DP/E2F factor, we hy-
pothesized that, by using UV cross-linking, we might un-
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Figure 1. Identification of a 30-kDa DNA-binding protein in Myb-sp.
(A) Complex formation employing nuclear extracts from the lymphoma
B-cell line DG-75 and radiolabeled E2F elements from the DHFR, CDC2
and MYB promoters were analyzed by EMSA. The position of com-
plexes I–V, containing p107, RB, free E2F or Myb-sp is indicated. The
free MYB-E2F probe is indicated. (B) Relative molecular weight estima-
tion of DNA-binding components of complexes formed with the MYB-
E2F probe. Ultraviolet (UV) cross-linking analysis of complexes I–V was
performed employing DG-75 nuclear extracts and a bromodeoxyuridine-
substituted MYB-E2F probe. Following native gel electrophoresis, the gel
was irradiated with UV light and the indicated complexes were excised
from the gel. Labeled proteins in the excised bands were then separated
by electrophoresis in a 10% SDS-PAGE. The gel mobility of pre-stained
protein molecular weight markers following compensation for the size of
the cross-linked probes (11 kDa) is indicated in kDa. The arrow indicates
the position of Myb-sp.
present in complexes I–IV. UV cross-linking of complexes
I–IV revealed strong and specific bands of 45–60 kDa (Fig-
ure 1B), which are consistent with the expected size of DP
and E2F subunits and with previous results using other E2F
elements or cells (13). In contrast, the only specific band
observed upon UV cross-linking of Myb-sp (complex V)
showed an apparent mass of 30 kDa (Figure 1B).
Myb-sp contains the transcription factor MYC-associated
zinc finger protein (MAZ)
To identify the 30-kDa-protein present in Myb-sp, we pu-
rified this factor by affinity chromatography. We had pre-
viously identified the key nucleotides of the MYB-E2F site
required for binding of either E2F factors or Myb-sp (5)
and used this information to design oligonucleotides that
bind only Myb-sp (MYB-Sp), only E2F (MYB-E2F) or no
factor (MYB-Null) (Figure 2A). As expected, complex for-
mation employing DG-75 nuclear extracts and the wild-
type (WT) probe (MYB-WT) was competed with a self-
oligonucleotide, but not with the Null mutant (Figure 2B).
Notably, the MYB-Sp oligonucleotide inhibited formation
of complex V, but did not affect complexes I-IV (Figure 2B).
In contrast, the MYB-E2F oligonucleotide inhibited com-
plexes I-IV, but did not affect complex V appearance (Fig-
ure 2B).
DNA affinity columns were then prepared by covalently
binding concatemerized MYB-Sp or MYB-Null oligonu-
cleotides to sepharose beads. Nuclear extracts from DG-75
cells were loaded onto both affinity columns and proteins
bound to the beads were eluted with an excess of Sp oligonu-
cleotides and fractionated through SDS-PAGE. The pres-
ence of a silver-stained band of 30 kDa (B30) was detected
only in the proteins eluted from the Sp column (Figure 2C).
Mass spectrometry analysis of tryptic peptides derived from
this band detected seven peptides that were unequivocally
identified as peptides from the MAZ family of zinc finger
proteins (Figure 2D and Supplementary Figure S1).
MAZ is expressed in humans as three major isoforms,
MAZ-1 (477 aa), MAZ-2 (493 aa) and MAZ-3 (454 aa)
(Figure 2E and Supplementary Figure S1) (24–26). A
shorter MAZ-2 protein, encompassing only aa 229–493
(hereafter referred to as MAZ-2s) has also been found (27).
MAZ-1 and MAZ-2 share 427 aa and differ only in their
carboxy-terminal tails, whereas the first 34 aa of MAZ-1
have been substituted in MAZ-3 by a sequence of 13 aa that
is not present in MAZ-1 or MAZ-2 (Figure 2E and Supple-
mentary Figure S1B). All isoforms contain a DNA-binding
domain, a nuclear localization signal, and several domains
that positively or negatively regulate transcription (Supple-
mentary Figure S2), as described for MAZ-1 (28).
While six of the seven tryptic peptides identified in band
B30 were common to all MAZ isoforms, one peptide was
found only in MAZ-2 or MAZ-2s (Figure 2D and Sup-
plementary Figure S1), strongly suggesting that MAZ-2
and/or MAZ2-s are present in Myb-sp. Since the theoreti-
cal mass of MAZ-2 (51 073 Da) is much larger than that of
the purified protein or that of the DNA-binding protein de-
tected by UV cross-linking, we hypothesized that the MAZ-
2 isoform present in Myb-sp might be MAZ-2s (theoretical
mass of 28 621 Da).
To determine whether MAZ-2s is the only MAZ pro-
tein in Myb-sp or if other MAZ family members might
also be present in this complex, we first tested the ability
of in vitro translated (IVT) MAZ-2s and MAZ-1 to bind
the MYB-E2F site in EMSA assays. As expected five ma-
jor complexes were observed employing a nuclear extract
from DG-75 cells (Figure 2F). A major complex, showing
a similar mobility to that of Myb-sp, was detected employ-
ing IVT MAZ-2s or MAZ-1 (Figure 2F). Formation of this
complex was efficiently competed by a self-oligonucleotide
and by its mutant derivative Sp, but not by its E2F or Null
mutant derivatives (Figure 2F). These results strongly sug-
gest that all MAZ proteins are capable of binding the MYB-
E2F site. Only one major complex, with a similar mobility
to that of complex III, was observed employing a control
reticulocyte lysate (Figure 2F). This complex appeared to
be specific and might perhaps contain E2F from the reticu-
locytes because its formation was efficiently competed by a
self-oligonucleotide and by its mutant derivative that binds
only E2F factors, but not by its mutant derivatives Sp or
Null (Figure 2F).
To further confirm that Myb-sp contains MAZ factors,
we generated antibodies against different MAZ isoforms
and used them as competitors in EMSA assays to iden-
tify the isoforms involved in complex formation. Peptides
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Figure 2. Myb-sp contains the transcription factor MAZ. (A) Sequence of WT and mutant MYB-E2F probes. For each mutant, alterations relative to
the WT sequence are indicated in bold. Lines indicate the binding sites for E2F and Myb-sp. (B) Complexes formed between DG-75 nuclear factors and
the radiolabeled MYB-E2F probe were analyzed by EMSA. Reaction mixtures were incubated in the absence (indicated as None) or in the presence of
a 100-fold excess of the indicated unlabeled competitor oligonucleotides. The position of complexes I–V is denoted. The free probe is not shown. (C) A
nuclear extract derived from DG-75 cells was subjected to sequence-specific DNA affinity chromatography employing concatemerized MYB-Sp or MYB-
Null oligonucleotides bound to sepharose beads. Samples were eluted with an excess of MYB-Sp oligonucleotides and analyzed by 10% SDS-PAGE and
silver staining. A 30-kDa band (B30) was excised and subjected to mass spectrometry analysis. (D) Sequence of the seven tryptic peptides derived from
B30. (E) Schematic representation of major MAZ isoforms. The Uniprot code of these isoforms and the approximate position of the detected peptides are
indicated. (F) EMSA analysis of complex formation employing the radiolabeled MYB-E2F probe and a nuclear extract from DG-75 cells (NE), a control
reticulocyte lysate (Mock) or in vitro translated MAZ-2s or MAZ-1. Reaction mixtures were incubated in the absence or in the presence of a 100-fold excess
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Figure 3. Production of antibodies against various MAZ isoforms. (A)
Schematic representation of major MAZ isoforms indicating the approx-
imate position of the peptides employed as immunogens in the produc-
tion of the indicated anti-MAZ antibodies. (B) Immunoblot analysis em-
ploying the indicated anti-MAZ antibodies and protein extracts derived
from HEK-293T overexpressing MAZ1, MAZ-2, MAZ-2s or from Mock-
transfected cells. Arrowheads indicate the position of the major proteins
identified by these antibodies.
2 or MAZ-2s were used as immunogens to generate poly-
clonal rabbit antibodies (Figure 3A). The specificity of these
antibodies was confirmed by immunoblot of cell lysates
from HEK-293T cells forced to express MAZ-1, MAZ-2
or MAZ-2s. The M-13 antibody, raised against a peptide
from the carboxy-terminal end of MAZ-1 and MAZ-3 (Fig-
ure 3A), specifically recognized ectopically expressed MAZ-
1 and a major endogenous protein of ∼30 kDa (Figure
3B). The M-2 antibody, raised against a peptide from the
carboxyl-terminal end of MAZ-2 (Figure 3A), detected ec-
topically expressed MAZ-2 and MAZ-2s and a major en-
dogenous protein of ∼30 kDa (Figure 3B). The M-123 anti-
body, raised against a peptide from the amino-terminal end
of MAZ-2s (common to all isoforms; Figure 3A), recog-
nized ectopically expressed MAZ-1, MAZ-2 and MAZ-2s
(Figure 3B). Of note, this antibody also hybridized strongly
with an ∼30-kDa-band in cell lysates from cells forced to
express full-length MAZ-1, suggesting the possibility that
these cells might express high levels of a smaller version of
MAZ-1 (MAZ-1s), similar to MAZ-2s. Finally, the M-12
antibody, raised against a peptide from the amino-terminal
end of MAZ-1 (identical to MAZ-2; Figure 3A), recognized
ectopically expressed MAZ-1 and MAZ-2, but not MAZ-2s
or any other endogenous protein with a relative mass close
to 30 kDa (Figure 3B).
Complex formation between the MYB-E2F probe and
IVT MAZ-2s tagged with HA was markedly affected by
an anti-HA antibody and by anti-MAZ antibodies M-2
and M-123 (Figure 4A). In contrast, the anti-MAZ M-12
and M-13, the M-123 pre-immune serum or an antibody to
Smad2/3 failed to shift the mobility of the complex (Figure
4A). A similar complex was observed employing IVT MAZ-
1 (Figure 4A) and its formation was inhibited by anti-MAZ
M-13 and M-123 antibodies, but not by anti-MAZ M-2
or anti-Smad2/3 antibodies or by pre-immune sera (Fig-
ure 4A). The M-12 antibody also failed to affect the for-
mation of this complex (Figure 4A), suggesting that it does
not work properly in EMSA assays. Together, these data in-
dicate that MAZ-1 and MAZ-2s are able to interact with
the MYB-E2F probe.
To determine if endogenous MAZ proteins are present in
Myb-sp, we used these anti-MAZ antibodies and the MYB-
E2F probe with nuclear extracts from DG-75 cells. M-13
and M-2 antibodies inhibited formation of the slower- and
the faster-migrating portion of complex V, respectively, and
the combination of both antibodies completely eliminated
complex V (Figure 4B). Formation of this complex was ab-
lated also by the M-123 antibody (Figure 4B). As expected,
the formation of E2F-containing complexes (I–IV) was in-
hibited by an anti-DP1 antibody, but not by any of the anti-
MAZ antibodies or their pre-immune sera (Figure 4B). The
M-12 and anti-HA antibodies and any of the MAZ pre-
immune sera failed to interfere with the formation of any
of these complexes (Figure 4B). These results indicate that
endogenous MAZ proteins are components of Myb-sp.
MAZ binding to the MYB-E2F site overcomes its repression
by RB family members and activates the MYB promoter
As we had suggested that binding of Myb-sp to the MYB-
E2F site prevented MYB promoter repression by RB fam-
ily members (5), we now investigated whether MAZ fac-
tors, as Myb-sp components, might overcome transcrip-
tional repression by pRB or p130. RB-deficient Saos-2 cells
were transfected with luciferase reporter plasmids (2xMYB-
BG-LUC) containing a TATA box and two copies of the
wild-type (WT) MYB-E2F site (Figure 5A). We also em-
ployed previously reported (5) mutant derivatives of this site
that bind only E2F, only Myb-sp (Sp) or no factor (Null).
Forced expression of MAZ-1, MAZ-2 and MAZ-2s trans-
activated the WT and Sp reporter, but not the E2F or the
Null derivatives (Figure 5B). In contrast, forced expression
of E2F1/DP1 transactivated the E2F reporter, but not the
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Figure 4. Myb-sp contains various MAZ isoforms. (A) EMSA analysis
of complex formation employing the radiolabeled MYB-E2F probe and a
control reticulocyte lysate (Mock), or in vitro translated MAZ-2s or MAZ-
1. Reaction mixtures were incubated in the absence (none) or in the pres-
ence of the indicated anti-MAZ antibodies, the M-123 pre-immune serum
(Pre-123) and an anti-HA or an anti-Smad2/3 antibody. The free probe is
not shown. (B) EMSA analysis of complex formation employing the radio-
labeled MYB-E2F probe and nuclear extracts from DG-75 cells. Reaction
mixtures were incubated in the absence (none) or in the presence of the
indicated anti-MAZ antibodies; the M-13, M-123 and M-12 pre-immune
sera (Pre-13, Pre-123 and Pre-12, respectively); and an anti-HA or an anti-
DP1 antibody. The free probe is not shown.
markedly reduced the activity of the WT and E2F reporters,
but not that of the construct driven only by the Sp deriva-
tive (Figure 5C–E). Finally, RB- and p130-mediated repres-
sion of the WT reporter, but not that of the E2F derivative,
was overcome by progressively increasing amounts of ei-
ther MAZ-2s or MAZ-1 (Figure 5C–E). Since MAZ-2s ac-
tivated transcription more poorly than MAZ-1 or MAZ-2,
we compared their levels in cells transfected with plasmids
encoding these isoforms together with WT and Sp reporter
vectors. While all MAZ isoforms were expressed at similar
levels, MAZ-2s showed less activation capacity than MAZ-
1 or MAZ-2 (Supplementary Figure S3).
To assess the regulation of MYB transcription by MAZ
factors on the complete human MYB promoter, we used a
reporter (MYBpr) in which luciferase expression was un-
der the control of the human MYB promoter (Figure 6A)
or derivatives in which its E2F site was mutated to bind
only E2F, only MAZ proteins (Sp) or no factor (Null), as
previously described (5). Saos-2 cells were cotransfected
with these reporter constructs and progressively increasing
amounts of MAZ-1 or MAZ-2s expression vectors. Anal-
ysis of the luciferase activity in extracts from these cells
showed that MAZ-1 and MAZ-2s activated the WT and
the Sp versions of the MYB promoter, but not its E2F or
Null mutant derivatives (Figure 6B-C). Together, these re-
sults suggest that MAZ specifically regulates the MYB pro-
moter in vivo via the MYB-E2F site (E2F/MAZ element).
Endogenous MAZ factors bind and activate the MYB pro-
moter in vivo and induce MYB expression
To determine whether MAZ regulates MYB expression not
only in tumor cell lines, but also in healthy primary cells,
we assessed its contribution to the regulation of the MYB
promoter in primary PBLs. MYB is not expressed in qui-
escent lymphocytes but its transcription is activated early
during the exit from quiescence and remains active there-
after (11,12). Since a previous report had shown inhibi-
tion of MYB promoter activity in HEK-293 cells by MAZ
through a GC box in the 5′UTR of MYB (29), we engi-
neered an additional reporter vector, MYBpr(+205), ex-
tending the MYB promoter with its 5′UTR that includes
the GC box (Figure 7A). The transfection efficiency of pri-
mary quiescent lymphocytes is extremely low, but under cer-
tain conditions it is sufficient to detect the activity of given
luciferase reporters (13). The WT and mutant derivative
MYBpr(+205) plasmids whose E2F/MAZ element could
interact only with E2F, only with MAZ (Sp) or with no fac-
tor (Null) were transfected in quiescent PBLs. Cells were
then left untreated or activated for 24 h with leucoagglu-
tinin plus interleukin-2 (IL2) to exit from quiescence. The
luciferase activity from resting and stimulated cells was
measured to assess the respective transactivation capacity
of each factor following lymphocyte activation. As shown
in Figure 7B, the reporter plasmids that contained a WT
E2F/MAZ site or its Sp mutant derivative were activated 3-
to 4-fold following cell stimulation, whereas reporter plas-
mids that contained its E2F or Null derivatives were not ac-
tivated, thus supporting the notion that MAZ binding to
the E2F/MAZ site is required for transcriptional induction
of MYB.
To determine whether MAZ was associated in vivo with
the human MYB promoter, ChIP assays were performed
with anti-MAZ M-123. Transcriptional activation of this
locus 2 h after the exit from quiescence was also assessed by
ChIP analysis of RNA Polymerase II (Pol II) binding to the
MYB locus. The products of PCR reactions performed with
DNA eluted from the immunoprecipitates were analyzed
by RT-qPCR. ChIP assays confirmed recruitment of both
MAZ and Pol II to a MYB promoter region encompassing
the E2F/MAZ site and the transcription initiation site in
cells activated in 2 h, but not in quiescent cells (Figure 7C).
According to the constitutive transcription of the gene en-
coding Pol II (POLR2A), ChIP analysis showed Pol II bind-
ing in quiescent and activated cells to its own promoter (Fig-
ure 7C). In contrast, MAZ was not bound to this promoter
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Figure 5. MAZ proteins bind the MYB-E2F element in vivo and over-
come RB-mediated transcriptional repression through this element.
ChIP assays using the M-123 pre-immune serum (Ctl) on
these two promoters and using the anti-MAZ and anti-Pol
II antibodies on the 3′-UTR of BMP7 excluded the pos-
sibility of co-precipitation of non-specific DNA sequences
(Figure 7C). These results therefore show that MAZ and
Pol II bind the MYB promoter in vivo 2h after the exit from
quiescence.
Since promoters cloned into reporter vectors might not
necessarily be regulated as in their chromosomal context,
we sought to determine the contribution of endogenous
MAZ proteins to the activation of the MYB gene. To this
end, we downregulated MAZ levels in primary cells through
lentivirus-mediated expression of MAZ shRNAs. A screen
of several MAZ shRNAs in the T-cell line Jurkat identi-
fied the high silencing capacity of shMAZ-A and shMAZ-
B on MAZ isoforms (Supplementary Figure S6). Because
lentiviral transduction of resting primary T lymphocytes is
poorly efficient, we stimulated their proliferation with leu-
coagglutinin and IL2 before infecting them. As previously
described (15), IL2 starvation of activated T lymphocytes
leads them back into a quiescent state, that can be readily
reverted through the addition of fresh stimuli (Figure 8A).
To confirm the quiescence of these cells, we assessed the ex-
pression levels of CCNG2 mRNA and p130, both markers
of G0 whose expression decreases during the exit from qui-
escence (9,30,31). We found that while their expression was
high in IL2-starved cells, it decreased markedly in stimu-
lated lymphocytes (Figure 8B and Supplementary Figure
S4). In contrast, the levels of E2F1 mRNA, a gene that is
not expressed in quiescent lymphocytes and that is induced
at the G1-S transition (32), were low in starved cells and
increased 16 h after lymphocyte stimulation (Figure 8C).
Under these conditions, MYB expression increased as
early as 1 h after T-cell re-stimulation (Figure 8B). How-
ever, RB family members inactivation, as determined by
phosphorylation of p130 and pRB, was not observed be-
fore 8 h from quiescence exit (Figure 8B). MAZ protein in
the nucleus and its mRNA levels were not substantially af-
←−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
(A) Schematic representation of the luciferase reporter plasmids used,
2xE2F/MAZ-Luc. Two copies of the WT E2F site from the MYB pro-
moter or its mutant derivatives that interact only with E2F (E2F), only
with MAZ (Sp) or with none of them (Null) were cloned immediately
upstream from the ß-globin TATA box in pBG-Luc. (B) The indicated
2xE2F/MAZ-Luc plasmids (1 g) were cotransfected with pRL-null (1
g) in asynchronously growing Saos-2 cells in the presence of plasmids
encoding MAZ-1 (0.1 g), MAZ-2 (0.1 g), MAZ-2s (0.1 g), DP1 (50
ng) plus E2F1 (50 ng) or empty vector (0.1 g). Forty hours later, cell
extracts were prepared and firefly and renilla luciferase assays were per-
formed. Firefly luciferase values were normalized for renilla activity. Lu-
ciferase activity is shown relative to that in the presence of the empty vector
(mean ± SEM; n = 4). **P < 0.01, ***P < 0.001 and ****P < 0.0001 ver-
sus Null; one-way ANOVA with Bonferroni post-test. (C–E) The indicated
2xE2F/MAZ-Luc (1 g) plasmids were cotransfected with pRL-null (1 g)
in asynchronously growing Saos-2 cells in the presence of 0.1 g of empty
vector (−), or plasmids encoding either (C and D) pRB (0.1 g) or (E)
p130, together with (C) MAZ-2s (0.1 or 0.5 g), (D) MAZ-1 (0.1 or 0.5
g) or MAZ-1 (0.5 g), as indicated. Forty hours later, cell extracts were
prepared and firefly and renilla luciferase assays were performed. Firefly
luciferase values were normalized for renilla activity. Luciferase activity is
shown relative to that in the presence of the empty vector (mean ± SEM;
n = 5). (C and D) *P < 0.05 and ****P < 0.0001 versus empty; ####P <
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Figure 6. MAZ proteins activate the MYB promoter through the
E2F/MAZ-binding element. (A) Schematic representation of the lu-
ciferase reporter vector driven by the MYB promoter (MYBpr-Luc). The
position of the E2F/MAZ combined element (black box) and that of the
transcription initiation site (arrow) is indicated. Reporter vectors with a
WT E2F/MAZ element (WT) as well as vectors with a mutated site that
interacted only with E2F (E2F), only with MAZ (Sp) or with none of them
(Null) were also generated. (B and C) The indicated MYBpr-Luc reporter
plasmids (10 g) were cotransfected with pRL-null (1 g) into Saos-2 cells
in the presence of empty vector (0) or increasing amount of plasmids (in-
dicated in g) encoding (B) MAZ-1 (n = 4) or (C) MAZ-2s (n = 3). Forty
hours later, cell extracts were prepared and firefly and renilla luciferase as-
says were performed. Firefly luciferase values were normalized for renilla
activity. Luciferase activity is shown relative to that in the presence of the
empty vector (mean ± SEM). *P < 0.05, **P < 0.01, ***P < 0.001 and
****P < 0.0001 versus Null; one-way ANOVA with Bonferroni post-test.
fected following exit from quiescence (Figure 8C and D). In
contrast, the nuclear presence of an ∼50 kDa MAZ form
phosphorylated at S460, a modification that enhances MAZ
DNA-binding activity (33), increased markedly 1 and 3 h af-
ter quiescence exit (Figure 8D). Immunofluorescence anal-
ysis of synchronized lymphocytes confirmed augmented
phospho-MAZ (S460) signal in the nucleus of cells 3h after
quiescence exit relative to unstimulated cells (Supplemen-
tary Figure S5).
Figure 7. Activation of the MYB promoter during the exit from quies-
cence requires its MAZ-binding site. (A) Schematic representation of the
luciferase reporter vector used, MYBpr(+205)-Luc. A DNA insert encom-
passing the MYB promoter plus its 5′UTR (a 205-bp DNA fragment) were
cloned into pGL2-Basic. Reporter vectors with a WT E2F/MAZ element
(WT) as well as vectors with a mutated site that interacted only with E2F
(E2F), only with MAZ (Sp) or with none of them (Null) were also gen-
erated. The relative positions of the combined E2F/MAZ element (black
box), the transcription initiation site (arrow) and the GC box (gray block)
are shown. (B) The indicated MYBpr(+205)-Luc reporter plasmids (40
g) were cotransfected with pRL-SV40 (5 g) into primary peripheral
blood lymphocytes (PBLs). Following transfection, cells were split and ei-
ther activated for 24 h with leucoagglutinin plus interleukin-2 to exit from
quiescence (Activated cells) or left untreated (Resting cells). Firefly and
renilla luciferase activities were measured in cell extracts from both acti-
vated and untreated cells. Normalized luciferase values for each indicated
reporter plasmid are shown relative to untreated cells (mean ± SEM; n =
8). **P < 0.01, ****P < 0.0001 versus Null Activated; two-way Anova with
Bonferroni post-test. (C) Anti-Pol II, anti-MAZ M-123 or pre-immune M-
123 (Ctl) ChIP analyses of resting lymphocytes (Res) and lymphocytes ac-
tivated for 2 h (Activ). Different dilutions of input chromatin DNA (1,
0.25 and 0. 1%) or DNA extracted from the indicated immunoprecipitates
were analyzed by real-time PCR using oligonucleotides flanking a MYB
genomic region encompassing the E2F/MAZ site and the transcription
initiation site (MYB), the transcription initiation site of POLR2A or the
3′-UTR of BMP7. Data are shown as enrichment in the amount of chro-
matin precipitated with each antibody relative to 0.1% input chromatin.
Histograms show means ± SEM (n = 3). **P < 0.01, ***P < 0.001 versus
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Figure 8. MAZ is required for MYB induction during the exit from quiescence. (A) Experimental timeline. The proliferation of isolated primary PBLs
was induced with a combination of leucoagglutinin and IL2 and maintained by the presence of IL2 during 12 days. Cells were then made quiescent by IL2
starvation and induced to re-enter the cell cycle 48 h later by adding leucoagglutinin and IL2. (B) Immunoblot analysis of p130 phospho-S672; p130 total;
a combination of pRB phospho-S780, phospho-S795 and phospho-S807/811; pRB total; and TFIIH (loading control) in nuclear extracts from these cells.
(C) RT-qPCR analysis of MYB, MAZ and E2F1 mRNA expression in lymphocytes stimulated for the indicated periods of time to re-enter the cell cycle.
mRNA amounts were normalized to GUSB expression. Data are shown as means ± SEM (n = 3) relative to 0 h. *P < 0.05, **P < 0.01, ***P < 0.001
versus 0 h; two-way ANOVA with Bonferroni post-test. (D) Immunoblot analysis of phospho-MAZ (S460) and MAZ total levels (employing the MAZ-123
antibody) in nuclear extracts from these cells. (E) Experimental timeline as in (A). Proliferating lymphocytes were transduced with lentivirus expressing
GFP and either a control shRNA or MAZ-specific shRNAs sh59 or sh60 2 days before IL2 starvation. (F and G) Lymphocytes transduced with lentivirus
expressing shRNAs as indicated were forced to become quiescent by IL2 starvation for 48 h. (E) MAZ knockdown was confirmed by RT-qPCR analysis at
this time. mRNA amounts were normalized to GUSB expression (means ± SEM, n = 3). ***P < 0.001, ****P < 0.0001 versus Control; one-way ANOVA
with Bonferroni post-test. (F) Transduced, quiescent cells were treated with leucoagglutinin plus IL2 for 1 h to re-enter the cell cycle (Activated) or left
untreated (Resting). MYB mRNA levels were determined by RT-qPCR analysis and normalized to GUSB expression (means ± SEM, n = 3). ***P <
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Ten days after the activation of T lymphocytes, we trans-
duced them with lentivirus co-expressing GFP and ei-
ther shMAZ-A or shMAZ-B (Figure 8E). The transduc-
tion efficiency under these conditions varied from 50 to
70% between experiments, as determined by flow-cytometry
analysis of GFP expression. These cells were IL2-starved
48 h after transduction to make them quiescent, and re-
stimulated 2 days later to induce MYB expression (Figure
8E). shMAZ-A and shMAZ-B decreased MAZ levels 60
and 50%, respectively (Figure 8F). Of note, MYB induc-
tion in these cells was also markedly decreased after 1 h of
stimulation relative to control cells (Figure 8G), indicating
that MAZ is a critical mediator of MYB induction during
the exit from quiescence. Together, our results strongly sug-
gest that the E2F/MAZ element plays a crucial role during
MYB activation in cells coming out of quiescence and that
MAZ binding to this element might be critical for the early
activation of MYB transcription.
DISCUSSION
We hypothesized that the interaction of proteins distinct
from E2F with the E2F-binding site in the MYB promoter
may prevent its transcriptional repression by E2F-recruited
RB family members. Here, we have identified these proteins
as members of the MAZ family of transcription factors. We
have shown that MAZ proteins bind the MYB-E2F site in
vitro and the MYB promoter in vivo and that they are crit-
ical not only to overcome transcriptional repression by RB
family members, but also to activate transcription and that
this regulation is essential for MYB induction during the
exit from quiescence.
The regulation of MYB transcription is particularly com-
plex because both its initiation and its elongation are crit-
ical. Its transcriptional initiation is regulated by several
factors, including MYB itself, NF-kB, JUN, PU.1 and
E2F (6,19,34–38). Indeed, forced E2F1 expression activates
MYB transcription through its E2F element (6), thus indi-
cating that this site can contribute to MYB promoter activa-
tion. E2F-mediated recruitment of RB family members to
transcriptional regulatory regions plays a dominant nega-
tive role on gene expression (8,9). Consequently, most E2F-
regulated genes are not activated before the G1-S transi-
tion, when RB family members are inactivated and released
from E2F-bound promoters through their CDKs-mediated
hyperphosphorylation. The MYB and MYC genes harbor
E2F sites in their regulatory regions and are therefore ex-
pected to remain repressed by the E2F/p130-containing
DREAM complex; both genes are activated however dur-
ing the exit from quiescence (11,12,39), much earlier than
the CDK-mediated inactivation of the RB family and its
release from E2F factors. We have previously reported that
two unidentified factors distinct from E2F, Myb-sp and
EMYCS, bind respectively the MYB and MYC promoters
through elements that overlap their E2F sites and proposed
that these factors might help these genes to overcome their
repression by RB family members during the exit from qui-
escence (5,13). EMYCS is unable to interact with the MYB-
E2F site and shows an apparent mass of 105 kDa (13),
whereas Myb-sp is unable to bind the MYC-E2F element
and its apparent mass is 30 kDa. It thus seems that different
E2F-regulated promoters are able to overcome RB family-
mediated repression in G1 through the occupancy of their
E2F sites by distinct proteins. EMYCS identity remains un-
known, but we have uncovered now that Myb-sp contains
MAZ proteins, also known as serum amyloid A activating
factor (SAF) and Pur-1 (40,41).
The MAZ family of zinc finger proteins was first identi-
fied as a transcription factor in the MYC promoter (24,42).
MAZ binds GC-rich sequences, namely GGGAGGG or
CCCTCCC, and plays an important role in modulating
TATA-less gene transcription (43–47). MAZ is expressed
ubiquitously at different levels in different tissues (48) and
regulates the expression of a variety of genes besides MYC,
including INS (40), CD4 (49), SAA1 (41), HTR2A (45),
PNMT (43), FIBG (50), CLCNKA (51), RASH (52) and
ADAM10 (53). Persistent high levels of MAZ are linked to
various pathophysiological conditions, including amyloido-
sis, rheumatoid arthritis, atherosclerosis and the terminal
phase of chronic myeloid leukemia (54–56). MAZ proteins
can play dual roles in transcriptional regulation depending
on the target gene; some promoters are activated (45,47,57),
while others are repressed (44,46).
MAZ also plays a role in transcription termination. In
particular, MAZ can repress transcriptional elongation of
MYB through its binding to a G-quadruplex structure
formed by a GGA repeat region (GC box) located in its
5′UTR (29). It therefore seems that MAZ plays a dual role
in MYB expression regulation by either activating or termi-
nating transcription through its binding to the E2F/MAZ
element in the promoter or to the G-quadruplex structure,
respectively. Net changes in MYB expression might there-
fore be regulated through preferential recruitment of MAZ
to the promoter or to the GGA repeat region. The interac-
tion of other transcription factors with MAZ or their bind-
ing to their corresponding elements in the MYB gene may
potentially increase MAZ affinity for one of its binding sites
and therefore promote gene activation or repression. Forced
expression of a non-specified MAZ isoform in HEK-293
cells decreased the activity of a transfected MYB regula-
tory region that included the promoter and its downstream
GGA repeat region (29). In contrast, using a similar reg-
ulatory region in primary T lymphocytes, we have shown
that the E2F/MAZ site in the MYB promoter is required
for its activation. Moreover, while MAZ knockdown failed
to affect MYB promoter regulation in HEK-293 cells (29),
we have shown that MAZ silencing in primary T lympho-
cytes greatly impaired MYB mRNA induction during the
exit from quiescence. The forced expression of a given MAZ
isoform in HEK-293 cells might account for the discrepant
result observed in MYB regulation. Supporting this hypoth-
esis, MAZ-1 and MAZ-2 have shown opposing effects on
the regulation of a reporter vector driven by three tandem
copies of the MAZ site in the SAA promoter (25). However,
using a reporter driven by two tandem copies of the MYB
E2F/MAZ site, we have shown that MAZ-1, MAZ-2 and
MAZ-2s activated transcription. Alternatively, our results
might suggest that the net effect of MAZ on MYB regula-
tion depends on the cell type or on the cell cycle status (con-
tinuously cycling cells versus cells exiting from quiescence),
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MAZ-1, MAZ-2 and MAZ-3 have been shown to reg-
ulate transcription of various genes (24–26) and we show
now that MAZ-1, MAZ-2 and MAZ-2s bind the MYB com-
bined E2F/MAZ site and activate transcription through
this element. Moreover, we show that MAZ proteins over-
come RB family-mediated transcriptional repression. In
addition, we have obtained evidence suggesting the exis-
tence of an additional MAZ isoform, MAZ-1s. The use of
the MAZ antibody M-13, raised against a peptide from
the carboxy-terminal end of MAZ-1 and MAZ-3, in im-
munoblot assays identified a major protein of ∼50 kDa,
the expected size of MAZ-1, in HEK-293T cells transfected
with MAZ-1. However, an additional protein of ∼30 kDa
was clearly detected also with this antibody in control cells
and the signal was even stronger in MAZ-1 transfected cells.
Whether this protein is the result of a new alternatively
spliced isoform, a cleavage product of MAZ-1 or the prod-
uct of an internal translation initiation site remains to be
elucidated.
Our UV cross-linking analysis showed that Myb-sp con-
tained a protein of ∼30 kDa, which is similar to the rela-
tive mobility of MAZ-1s and MAZ-2s. Mass spectrometry
analysis of this protein revealed six peptides common to all
MAZ isoforms and an additional peptide that was present
only in MAZ-2 and MAZ-2s. These results might suggest
that MAZ-2s is the protein present in Myb-sp, but the in-
hibition of Myb-sp complex formation in EMSA assays by
an antibody to MAZ-1/MAZ-3 (M-13) and the reactivity
of this antibody to a short MAZ-1 isoform (or degradation
product) of ∼30 kDa, rather support the notion that at least
MAZ-1 and MAZ-2 (or their short isoforms) can regulate
MYB expression through the combined E2F/MAZ site.
MAZ phosphorylation by various kinases regulates its
activity. In particular, its phosphorylation at S460 by ca-
sein kinase II (CKII) increases MAZ DNA-binding ac-
tivity (33). MAZ phosphorylation at T72 by the mitogen-
activated protein kinase signaling pathway (58) or at S187
and T386 by protein kinase A (59) also increases MAZ ac-
tivity. We could not assess MAZ phosphorylation at T72,
S187 or T386 during the exit from quiescence, but we have
found that MAZ S460 phosphorylation was markedly in-
duced as early as 1 and 3 h after entry in the cell cycle.
We therefore propose a model by which phosphorylation-
mediated MAZ activation early after the exit from quies-
cence increases MAZ binding to the MYB promoter, likely
through the E2F/MAZ element, alleviating DREAM-
mediated repression until the phosphorylation-mediated in-
activation of RB family members late in G1.
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